THE COST-EFFECTIVENESS OF ATIDARSAGENE AUTOTEMCEL (ARSA-CEL) FOR THE TREATMENT OF METACHROMATIC LEUKODYSTROPHY (MLD) IN THE US

被引：0
|
作者：
Pang, F. [1 ]
Dean, R. [2 ]
Jensen, I. S. [2 ]
Bean, K. [1 ]
Fields, C. [3 ]
Miller, B. [2 ]
机构：
[1] Orchard Therapeut Ltd, London, England
[2] Precis Hlth Econ Outcomes Res, Boston, MA USA
[3] Orchard Therapeut Ltd, Boston, MA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE393
引用
收藏
页码：S126 / S126
页数：1
相关论文
共 50 条
  • [11] TREATMENT PATTERNS AND COST OF CARE AMONG PATIENTS WITH METACHROMATIC LEUKODYSTROPHY (MLD) IN THE US
    Mohajer, A.
    Lewis, A.
    Bean, K.
    Fields, C.
    Pang, F.
    VALUE IN HEALTH, 2023, 26 (12) : S515 - S515
  • [12] A systematic review of clinical effectiveness and safety for historical and current treatment options for metachromatic leukodystrophy in children, including atidarsagene autotemcel
    Nigel Armstrong
    Andrew Olaye
    Caro Noake
    Francis Pang
    Orphanet Journal of Rare Diseases, 18
  • [13] Cost-effectiveness framework by tandem mass spectrometry (TMS) for newborn screening of metachromatic leukodystrophy (MLD) in the United States (US)
    Bean, Karen
    Gelb, Michael H.
    Adang, Laura A.
    Chanson, Charlotte
    Pang, Francis
    MOLECULAR GENETICS AND METABOLISM, 2024, 141 (02)
  • [14] A COMPARISON OF GENERALIZED RISK ADJUSTED COST-EFFECTIVENESS ANALYSIS (GRACE) VS TRADITIONAL COST-EFFECTIVE ANALYSIS (CEA) ESTIMATES FOR THE TREATMENT OF EARLY-ONSET METACHROMATIC LEUKODYSTROPHY (MLD)
    Ortega, L.
    Incerti, D.
    Bean, K.
    Fields, C.
    Pang, F.
    Lakdawalla, D.
    VALUE IN HEALTH, 2024, 27 (12) : S73 - S73
  • [15] COST-EFFECTIVENESS OF TESAMORELIN IN THE TREATMENT OF LIPOHYPERTROPHY IN THE US
    Azimpour, K.
    Tremblay, G.
    de Chantal, M.
    Marsolais, C.
    VALUE IN HEALTH, 2020, 23 : S175 - S175
  • [16] The cost-effectiveness of ibandronate in the treatment of postmenopausal osteoporosis in the US
    Earnshaw, SR
    Graham, CN
    Amonkar, MM
    Barr, CE
    VALUE IN HEALTH, 2006, 9 (03) : A163 - A163
  • [17] Cost-effectiveness of eszopiclone for the treatment of adults with primary insomnia in the US
    Bell, C.
    Snedecor, S. J.
    Botteman, M. F.
    Schaefer, K.
    Pickard, A. S.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 305 - 305
  • [18] Comparative Cost-effectiveness Of Hypertension Treatment Guidelines In US Adults
    Penko, Joanne
    Bellows, Brandon K.
    Hennessy, Susan
    Kazi, Dhruv S.
    Coxson, Pamela
    Bibbins-Domingo, Kirsten
    Moran, Andrew E.
    HYPERTENSION, 2022, 79
  • [19] Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States
    Herring, William L.
    Gallagher, Meghan E.
    Shah, Nirmish
    Morse, Kc
    Mladsi, Deirdre
    Dong, Olivia M.
    Chawla, Anjulika
    Leiding, Jennifer W.
    Zhang, Lixin
    Paramore, Clark
    Andemariam, Biree
    PHARMACOECONOMICS, 2024, 42 (06) : 693 - 714
  • [20] Therapies for treatment of osteoporosis in US women: Cost-effectiveness and budget impact considerations
    Tosteson, Anna N. A.
    Burge, Russel T.
    Marshall, Deborah A.
    Lindsay, Robert
    AMERICAN JOURNAL OF MANAGED CARE, 2008, 14 (09): : 605 - 615
12345